Novo Nordisk cut to Underweight by Morgan Stanley
Morgan Stanley downgraded Novo Nordisk from equal-weight to underweight and maintained a $40.00 share price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.